Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Veeva (VEEV) to $215 from $205 and keeps an Equal Weight rating on the shares. Against the backdrop of “pervasive negative sentiment” in software and healthcare IT, FY26 ending on a high note and FY27 guidance that was “a touch ahead of the Street” should “drive a relief rally,” but follow through will depend on subscription growth in the coming quarters, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva price target raised to $215 from $205 at Morgan Stanley
- Veeva price target raised to $245 from $212 at Stifel
- Veeva price target raised to $235 from $200 at Canaccord
- Strong Near-Term Execution but Uncertain Long-Term Growth Drivers Justify Hold on Veeva
- Veeva price target lowered to $317 from $333 at Wells Fargo